文献速递生殖医学

通用植入前单基因病遗传学检测(Karyomapping):诊断超过1000种独特疾病且未检测到误诊

Universal preimplantation genetic testing for monogenic disease (Karyomapping): diagnosis of >1000 unique disorders with no detected misdiagnoses.
PubMed 文献 · Hum Reprod · 2025-01-01

该研究于2014年1月至2021年12月在一个诊断基地对9020例植入前单基因病遗传学检测(PGT-M)应用Karyomapping,共诊断1017种独特疾病(涉及912个基因)。通过直接测序对73%的病例(4120个突变)进行验证,所有可检测的诊断均准确,未检测到误诊。

要点

  • Karyomapping可诊断超过1000种单基因病,在9020例PGT-M中覆盖1017种疾病。
  • 对73%的病例(4120个突变)进行直接测序验证,未检测到误诊。
  • 局限性包括依赖参考样本和父母基因组DNA,端粒附近位点检测可能受限。

核心结论

  • 在9020例PGT-M中,Karyomapping诊断了超过1000种不同疾病;对超过70%的病例进行独立验证未检测到误诊。
  • Karyomapping是目前最常用的PGT-M方法;随着DNA测序新方法的应用,通过整合Karyomapping原理并纳入染色体拷贝数分析,所有遗传病的植入前遗传学检测成为可能。

研究设计与样本

  • 研究于2014年1月至2021年12月在一个诊断基地进行,使用Karyomapping对9020例PGT-M病例进行检测。
  • 所有病例均涉及滋养层活检和胚胎玻璃化冷冻;尽可能从父母双方及患病参考家庭成员获取颊刷样本DNA。
  • 对胚胎活检样本的全基因组扩增DNA和基因组DNA进行SNP微阵列分析;Karyomapping按照制造商说明在BlueFuse Multi软件中进行分析。
  • 通过分析2 Mbp侧翼窗口内10个支持的5'和3'关键SNP确定风险等位基因的遗传来源;尽可能使用Sanger测序进行直接突变检测。

主要发现

  • 共从912个基因的突变中检测到1017种独特疾病。
  • 在73%的病例中通过直接测序对4120个突变进行验证,确认所有可检测的诊断均准确。
  • 在27%无法确认结果的病例中,无法对误诊率发表评论。

临床怎么用

  • Karyomapping是目前最常用的PGT-M方法。
  • 作者认为,随着DNA测序新方法的应用,通过整合Karyomapping原理并纳入染色体拷贝数分析,所有遗传病的植入前遗传学检测成为可能。

局限性

  • Karyomapping可能受参考样本和父母基因组DNA可用性的限制。
  • 由于SNP阵列而非Karyomapping算法本身的限制,某些端粒附近位点可能更难以检测。
  • 在27%无法确认结果的病例中,无法对误诊率发表评论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can a universal diagnostic test (Karyomapping) be applied for preimplantation genetic testing for multiple monogenic disorders (PGT-M) and what is the misdiagnosis rate? SUMMARY ANSWER: Among 9020 cases of PGT-M, >1000 different disorders were diagnosed by Karyomapping; independent validation of >70% of cases did not detect a misdiagnosis. WHAT IS KNOWN ALREADY: PGT-M, first performed in 1992, has been used for ∼40 000 clinical cases worldwide. A limiting factor in direct testing for disease mutations, however, is the need to design assays specific for each affected allele. Karyomapping, based on haplotype phasing using SNP microarrays, was developed in 2010 as a single, method tracing inheritance of any monogenic disorder. Karyomapping eliminates the impact of allele drop-out and DNA contamination on test accuracy and facilitates a short work-up time as the same assay platform is used for every case. STUDY DESIGN, SIZE, DURATION: Here, we used Karyomapping on a large PGT-M series from one diagnostic base from January 2014 to December 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 9020 individual Karyomapping cases were performed in three CooperSurgical genetic testing laboratories, in Livingston NJ, Michigan, or London (UK). All cases involved trophectoderm biopsy with embryo vitrification. DNA from cheek brush samples was obtained from both parents and an affected reference family member where possible. Genomic DNAs and that of whole genome amplified DNA from embryo biopsies were subjected to SNP microarray. Karyomapping was performed according to manufacturer's instructions by first importing into BlueFuse Multi software. Inheritance was determined as to where at-risk allele(s) were inherited, with 10 supporting 5' and 3' Key SNPs in a 2 Mbp flanking window. Wherever possible, direct mutation testing was performed using Sanger sequencing. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 1017 unique disorders were detected from mutations in 912 genes. Validation of 4120 mutations was possible in 73% of cases by direct sequencing, which confirmed that all diagnoses that could be assayed were accurate. LIMITATIONS, REASONS FOR CAUTION: Karyomapping can be limited by the availability of a reference, as well as parental genomic DNA, and some loci near the telomere may be more difficult to detect because of the limitations of the SNP array rather than the Karyomapping algorithm. Of the 27% of cases where we could not confirm the findings, we cannot comment on the misdiagnosis rate. WIDER IMPLICATIONS OF THE FINDINGS: Karyomapping is now the single most used approach for PGT-M. As new approaches increasingly involve DNA sequencing, PGT for all genetic disease becomes possible by encapsulating the principles of Karyomapping and incorporating chromosome copy number analysis. TRIAL REGISTRATION NUMBER: N/A. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by CooperSurgical. The PhD programs of A.S. and O.W. were supported by CooperSurgical (paid to institution). A.S. has received travel support and IT equipment from CooperSurgical. O.W. has received travel support and provision of a company laptop from CooperSurgical. L.X., P.C., E.B., and T.G. are employees of and hold stock/share ownership in CooperSurgical. N.-N.G. is an employee of, has received meeting registration fees from, and holds stock/share ownership in CooperSurgical. L.R. is an employee of CooperSurgical. D.K.G. has received consulting fees and travel support from CooperSurgical. P.E. has nothing to declare.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Schadwell A, Whiting O, Xanthopoulou L, et al. Universal preimplantation genetic testing for monogenic disease (Karyomapping): diagnosis of >1000 unique disorders with no detected misdiagnoses. Hum Reprod. 2025. PMID: 41139420. doi:10.1093/humrep/deaf198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。